Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Churg-Strauss syndrome: update on recent developments.

W L Gross1

  • 1Department of Rheumatology, Medical University of Luebeck, Hospital for Internal Medicine and Clinical Immunology, Rheumaklinik Bad Bramstedt, Germany. gross@rheuma-zentrum.de

Current Opinion in Rheumatology
|January 16, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Not Available].

Der Internist·2016
Same author

[Future integrated health care in internal medicine: primary hypertension and polyangiitis with granulomatosis as modell diseases].

Deutsche medizinische Wochenschrift (1946)·2015
Same author

[Genetic architecture of chronic inflammatory diseases].

Der Internist·2014
Same author

[Genetic risk factors for vasculitis].

Der Internist·2013
Same author

Genetics of toll like receptor 9 in ANCA associated vasculitides.

Annals of the rheumatic diseases·2013
Same author

[Hypereosinophilic syndrome].

Der Internist·2013

Churg-Strauss syndrome (CSS) is an allergic vasculitis involving multiple organs. New markers may predict relapses, but its exact cause and treatment effectiveness require further study.

Area of Science:

  • Immunology
  • Rheumatology
  • Pathology

Background:

  • Churg-Strauss syndrome (CSS) is a primary vasculitis characterized by allergy and angiitis.
  • Eosinophilic infiltration is a key feature in affected organs, with eosinophilia and elevated IgE as prominent laboratory findings.
  • The exact pathophysiology and etiology of CSS remain incompletely understood, with ongoing debate regarding its immune mediation.

Purpose of the Study:

  • To review the key characteristics, diagnostic markers, and treatment strategies for Churg-Strauss syndrome.
  • To highlight potential new seromarkers for predicting disease relapse.
  • To discuss the current understanding of CSS etiology and pathophysiology, including cytokine involvement.

Main Methods:

  • Literature review of Churg-Strauss syndrome, focusing on clinical presentation, laboratory findings, and diagnostic markers.

Related Experiment Videos

  • Analysis of current treatment protocols, including glucocorticoids and other immunosuppressive agents.
  • Examination of emerging research on seromarkers and cytokine profiles in CSS.

    • Main Results:

    • Eosinophilia, normocytic anemia, and elevated IgE are key laboratory findings in CSS.
    • New seromarkers like soluble thrombomodulin and eosinophil cationic protein may indicate disease activity and predict relapse.
    • Antineutrophil cytoplasmic antibodies are present in about half of patients, with questionable diagnostic utility.
    • Interleukin-5 and tumor necrosis factor-alpha are elevated, suggesting potential therapeutic targets.
    • Glucocorticoid monotherapy is the standard treatment, though data on other immunosuppressants is limited.
    • Interferon-alpha has shown efficacy in refractory cases.

    Conclusions:

    • CSS is a complex allergic vasculitis with diverse organ involvement.
    • Further research is needed to fully elucidate CSS pathophysiology and optimize treatment strategies.
    • Novel seromarkers and targeted cytokine therapies hold promise for future management of Churg-Strauss syndrome.